Molecure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Molecure şirketinin toplam hissedar öz sermayesi PLN80.1M ve toplam borcu PLN0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla PLN87.7M ve PLN7.6M dir.

Anahtar bilgiler

Borç/özkaynak oranı

zł0

Borç

Faiz karşılama oranı	n/a
Nakit	zł28.58m
Eşitlik	zł80.09m
Toplam yükümlülükler	zł7.62m
Toplam varlıklar	zł87.71m

Son finansal sağlık güncellemeleri

Recent updates

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Aug 20

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Apr 20

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Dec 01

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Jul 07

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Mar 10

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Aug 16

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Nov 04

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

Feb 24

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

Jan 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: MOC 'nin kısa vadeli varlıkları ( PLN30.2M ) kısa vadeli yükümlülüklerini ( PLN3.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: MOC şirketinin kısa vadeli varlıkları ( PLN30.2M ) uzun vadeli yükümlülüklerini ( PLN4.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: MOC borçsuzdur.

Borcun Azaltılması: MOC son 5 yıldır borcu bulunmamaktadır.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: MOC şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: MOC un, serbest nakit akışı her yıl % 13 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Molecure Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Recent updates

New minor risk - Share price stability

New minor risk - Profitability

Price target decreased by 22% to zł23.25

Second quarter 2024 earnings released: zł0.46 loss per share (vs zł0.29 loss in 2Q 2023)

Is Molecure (WSE:MOC) In A Good Position To Deliver On Growth Plans?

New major risk - Revenue and earnings growth

New minor risk - Financial position

No longer forecast to breakeven

Molecure S.A. Receives Approval to Initiate A Phase II Clinical Trial (KITE) for OATD-01 for the Treatment of Pulmonary Sarcoidosis in Selected Countries of the European Union and Norway

Molecure S.A., Annual General Meeting, Jun 13, 2024

New minor risk - Financial data availability

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A. Announces First Patient in the OATD-01 Phase 2 KITE Study in Pulmonary Sarcoidosis

Molecure S.A. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Revenue and earnings growth

Molecure S.A Announces No Grant of Permission to Conduct Phase II Clinical Trials for the OATD-01 Molecule I

We're Keeping An Eye On Molecure's (WSE:MOC) Cash Burn Rate

Third quarter 2023 earnings released: zł0.25 loss per share (vs zł0.16 loss in 3Q 2022)

Second quarter 2023 earnings released

New minor risk - Share price stability

New minor risk - Shareholder dilution

Molecure S.A. Receives Clearance from the U.S. Food and Drug Administration on its Investigational New Drug Application to Conduct Phase II Clinical Testing of OATD-01

Molecure S.A. announced that it has received PLN 49.968 million in funding

Is Molecure (WSE:MOC) In A Good Position To Invest In Growth?

Molecure S.A., Annual General Meeting, May 31, 2023

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A. to Report Q1, 2023 Results on Apr 28, 2023

Molecure S.A. Announces Management Changes

Molecure S.A. to Begin Clinical Development of Novel Dual Arginase Inhibitor Oatd-02 for the Treatment of Cancer After Gaining Permission to Conduct First Clinical Trial in Poland

Third quarter 2022 earnings released: zł0.16 loss per share (vs zł0.13 loss in 3Q 2021)

Second quarter 2022 earnings released: zł0.27 loss per share (vs zł0.20 loss in 2Q 2021)

Companies Like Molecure (WSE:MOC) Are In A Position To Invest In Growth

Molecure S.A., Annual General Meeting, Jun 30, 2022

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

OncoArendi Therapeutics S.A. Announces Board Appointments

OncoArendi Therapeutics S.A Appoints Samson Fung as Chief Medical Officer

OncoArendi Therapeutics' (WSE:OAT) Earnings Are Weaker Than They Seem

Second quarter 2021 earnings released: zł0.21 loss per share (vs zł0.034 loss in 2Q 2020)

CEO & President of Management Board recently bought zł178k worth of stock

Is OncoArendi Therapeutics S.A.'s (WSE:OAT) Shareholder Ownership Skewed Towards Insiders?

OncoArendi Therapeutics S.A. to Report Q2, 2021 Results on Sep 27, 2021

Will OncoArendi Therapeutics (WSE:OAT) Spend Its Cash Wisely?

New 90-day high: zł57.80

OncoArendi Therapeutics SA and Galapagos Enter into Exclusive Collaboration on Chitinase Inhibitors in Fibrosis

Third quarter 2020 earnings released: zł0.06 loss per share

First half earnings released

New 90-day high - zł19.70

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin